Navigation Links
Pharmaceutical Marketing Strategy Balances Support Between New & Established Products in the Same Indication
Date:9/23/2011

CHAPEL HILL, N.C., Sept. 23, 2011 /PRNewswire/ -- A pharmaceutical company's marketing strategy must undergo many critical changes to avoid cannibalization when introducing a new brand in a space where the company already has an established brand. For more than two-thirds of companies, the most frequent changes require shifting resources and funds to support the new product through activities, such as professional relations, promotional literature, sampling, and advisory boards/thought leader development.

However, spending priorities for the legacy product must shift as well. On average, sampling, coupon-discount programs and direct mail become more important, while ad boards, class-building activities and speaker training become less important for the legacy brand's continued success, according to "Expanding a Product Portfolio without Cannibalizing an Established Brand," primary research conducted by Best Practices, LLC.

Download a complimentary white paper at http://www3.best-in-class.com/rr1120.htm that includes selected best practices drawn from extensive primary research with brand leaders from 22 different pharmaceutical, biotechnology and medical device companies.

"Expanding a Product Portfolio without Cannibalizing an Established Brand" is a 61-page report with more than 130 benchmark metrics and 37 executive narratives, providing marketing and brand executives with valuable insights and exhaustive data to plan and implement marketing strategies for multiple, high-performing brands in the same indication.

For more information on this study and other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.  

BEST PRACTI
'/>"/>

SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
2. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
3. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
4. Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets
5. Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets
6. Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
7. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
8. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on North America
9. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on Europe
10. Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
11. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Jan. 31, 2012 Halozyme Therapeutics, Inc. (NASDAQ: ... Phase 1 proof-of-concept and local tolerability study of HTI-501 ... 8th World Congress of the International Academy of Cosmetic ... commencement of the Phase 2 portion of the clinical ...
... LAKES, N.J., Jan. 31, 2012 The Board of Directors of ... declared a quarterly dividend of 45 cents per common share, payable ... 2012. The indicated annual dividend rate is $1.80 per share. ... is a leading global medical technology company that develops, manufactures and ...
Cached Medicine Technology:HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 2HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 3
(Date:9/30/2014)... [Brown University] Autism is no stranger to the ... African nation is access to clinical services, including reliable ... measure, for example, validated for use in Swahili, a ... study, however, researchers at Brown University and the University ... that they implemented at two sites in the country ...
(Date:9/30/2014)... passed in 2003 to slow the spiraling costs of ... Medicare patients has had no meaningful impact on cancer ... the Journal of Clinical Oncology published online ... to treat colorectal and lung cancers, and did not ... drugs following the implementation of the recent Medicare law ...
(Date:9/30/2014)... 2014 Dynamic health trends, changing ... in the Bread Production industry over the past ... moderate their consumption of a variety of industry ... shrunk the market for white loaf bread and ... by introducing more nutritious products to attract health-conscious ...
(Date:9/30/2014)... (FQHCs) granted new patient appointments to Medicaid beneficiaries ... primary care practices (non-FQHCs), in addition to charging ... new 10-state University of Pennsylvania study published this ... data from a previous "secret shopper" study conducted ... FQHCs community health clinics that receive federal ...
(Date:9/30/2014)... September 30, 2014(BRONX, NY)Medications are the leading cause of ... analysis of death certificates from 1999 to 2010, conducted ... and Albert Einstein College of Medicine of Yeshiva ... Journal of Allergy and Clinical Immunology , also ... was particularly high among older people and African-Americans and ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2
... Field, IRVING, Texas, Sept. 11 Over 90 ... solicitations during their training,and 80 percent received two dozen ... Merritt, Hawkins & Associates, a national physician,search firm based ... "Like blue chip athletes, new doctors are the ...
... 11 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX,: HAE), ... plasma-derived protein products for commercialization,disclosed today the ... on the use of its proprietary lead ... preventing the formation of post-surgical,adhesions in a ...
... scoop, NEW YORK, Sept. 11 If ... impact a person,s body and skin, it,s a ... procedures last,year to improve their appearances. However, New ... can improve your appearance,without going under the knife!, ...
... will be of great interest to employers and employee benefit brokers ... grounbreaking wellness and health management tool designed to help control costs ... ... (PRWEB) September 11, 2008 -- U.S. Preventive Medicine, the leader in ...
... for the medical tourism industry. Working closely with medical tourism ... trip cancellation insurance products to meet the needs of the industry. ... ... Clements International develops unique suite of insurance solutions for the medical ...
... a traumatic injury can have serious and long-lasting ... the largest-ever U.S. study evaluating the impact of ... and Research Center, the University of Washington, and ... found that post-traumatic stress disorder and depression were ...
Cached Medicine News:Health News:Survey: New Doctors Receive Dozens of Job Solicitations 2Health News:Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model 2Health News:Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model 3Health News:Insider Secrets for Beautiful Skin 2Health News:U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan 2Health News:U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan 3Health News:U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan 4Health News:Clements International Develops Insurance for Medical Tourism Industry 2Health News:National study finds post-traumatic stress disorder common among injured patients 2